suberoyl bis-hydroxamic acid has been researched along with lithium chloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, JT; Chen, H; Hottinger, DG; Kunnimalaiyaan, M | 2 |
2 other study(ies) available for suberoyl bis-hydroxamic acid and lithium chloride
| Article | Year |
|---|---|
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoid Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Enzyme Inhibitors; Gastrointestinal Neoplasms; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Lithium Chloride; Luciferases; Lung Neoplasms; Receptor, Notch1; Valproic Acid | 2009 |
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Topics: Cell Division; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lithium Chloride; Receptor, Notch1; Thyroid Neoplasms; Tumor Cells, Cultured; Up-Regulation; Valproic Acid | 2010 |